anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To describe a novel technique, posterior thoracic antidisplacement and fusion (PTAF), for a special type of ossification of the posterior longitudinal ligament in the thoracic spine (T-OPLL), and to evaluate its safety and efficacy.
METHODS: From July to December 2020, 5 consecutive patients with beak-type T-OPLL located at the thoracic vertebral body level underwent PTAF surgery. Their demographic data, radiological parameters, perioperative complications, and surgery-related findings were recorded and analyzed. The surgical outcomes were assessed using a modified Japanese Orthopedic Association scale, and the recovery rate was calculated using the Hirabayashi's method.
RESULTS: All patients were followed up for at least two years. The mean thickness of OPLL was 9.4 ± 1.0 mm, and the OPLL spinal canal occupying ratio was 67.7% ± 8.5%. Postoperatively, the mean antidisplacement distance of OPLL was 8.1 ± 1.8 mm, and the average shortened distance of the spinal column was 6.0 ± 1.13 mm. The mean operation time and blood loss were 158.2 ± 26.3 minutes and 460 ± 89.4 mL, respectively. Perioperative complications were cerebrospinal fluid leakage and instrument failure, 2 cases each. The mean modified Japanese Orthopedic Association score was increased from 3.6 ± 2.9 before surgery to 9.4 ± 3.0 at the last follow-up, and the average recovery rate was 84.2 ± 30.5%.
CONCLUSIONS: The preliminary clinical outcomes indicate that PTAF is a safe and effective method for the treatment of beak-type T-OPLL, which has its apex located at the vertebral body level and has a high spinal canal occupation ratio.
A therapeutically useful preparation consists essentially of a colloidal hydrated antimonic acid -partially depolymerized dextran complex.  The depolymerized dextran may be obtained by growing Leuconostoc Mesenteroides and then treating the resultant dextran by acid hydrolysis.  In examples, antimony pentachloride or antimony trioxide is dissolved in hydrochloric acid, which may contain nitric acid, and the whole is diluted with distilled water and then added with stirring to a dilute solution of low molecular weight dextran (intrinsic viscosity of 0,05 to 0,06) in caustic soda to obtain a product having a pH of 4 to 7; after boiling it is freed from electrolyte by repeated precipitation with ethyl alcohol and the aqueous solution braded into ampoules and sterilized.  It may be used in the treatment of tropical diseases such as leischmaniasis and schistosomiasis.ALSO:A therapeutically-useful preparation consists essentially of a colloidal hydrated antimonic acid-partially depolymerized dextran complex.  It may be made according to the method described in Group IV (a) by heating a solution of antimony trichloride or antimony trioxide in mineral acid with acid hydrolysed dextran in caustic soda.  The neutralized product may be repeatedly precipitated by alcohol and the aqueous solution loaded into ampoules and sterilized at 115 DEG  to 116 DEG  C. for at least 30 minutes. It may be used in the treatment of tropical diseases such as leischmaniosis and schistomiosis.
BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is quickly becoming a routine and effective means by which to treat degenerated bioprosthetic valves. A known complication of ViV-TAVI is patient-prosthesis mismatch, which substantially affects survival. Bioprosthetic valve fracture is a method by which to reduce the risk of patient-prosthesis mismatch and post-ViV-TAVI transvalvular gradients. This study sought to determine the safety and efficacy of post-ViV-TAVI bioprosthetic valve fracture.
METHODS: Patients with a history of surgical aortic valve replacement undergoing ViV-TAVI bioprosthetic valve fracture (N = 25) at the corresponding institution from 2015 to 2022 were cataloged for a retrospective analysis. The implanted transcatheter valves were Medtronic Evolut R, Evolut PRO, and Evolut PRO+. Gradients were assessed before and after implantation and after fracturing using transthoracic echocardiogram.
RESULTS: The mean left ventricular ejection fraction of patients who underwent fracturing was 55.04%. The average (SD) peak and mean (SD) transvalvular gradients before the intervention were 68.17 (19.09) mm Hg and 38.98 (14.37) mm Hg, respectively. After ViV-TAVI, the same gradients were reduced to 27.25 (12.27) mm Hg and 15.63 (6.47) mm Hg, respectively. After bioprosthetic valve fracture, the gradients further decreased to 17.59 (7.93) mm Hg and 8.860 (3.334) mm Hg, respectively. The average reduction in peak gradient associated with fracturing was 12.07 mm Hg (95% CI, 5.73-18.41 mm Hg; P = .001). The average reduction in mean gradient associated with valve fracturing was 6.97 mm Hg (95% CI, 3.99-9.74 mm Hg; P < .001).
CONCLUSION: Bioprosthetic valve fracture is a viable option for reducing residual transvalvular gradients after ViV-TAVI and should be considered in patients with elevated gradients (>20 mm Hg) or with concern for patient-prosthesis mismatch in patients who have an unacceptable risk for a redo sternotomy and surgical aortic valve replacement.
The invention relates to a nutritional composition comprising at least one N-acetylated oligosaccharide, and at least one galacto-oligosaccharide, and at least one sialylated oligosaccharide. The composition optionally comprises a  Bifidobacterium animalis  spp.  lactis  probiotic, preferably CNCM-I-3446 probiotic. The composition treat ro reduces the risk, the severity and/or the occurrence of non-rotavirus associated diarrhoea. The composition also promotes a healthy intestinal flora and has beneficial long and short terms effects. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula.
One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneamine. In a preferred embodiment, the polyalkyleneamine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneamine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneamine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneamine bearing photopolymerizable groups with ultraviolet or visibile light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneamine. In a preferred embodiment, the polyalkyleneamine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneamine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.
Clinical studies of Penicillin G Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Penicillin G Injection contains 6.8 mg (0.3 mEq) of sodium per million units. At the usual recommended doses, patients would receive between 6.8 and 163.2 mg/day (0.3 and 7.2 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.
FIELD: medicine/pharmaceuticals.SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals. 1-3 objects are a chimeric mouse and human antibody that binds to amyloid fibrils and contains the VKregions of SEQ ID NO: 47 and VHof SEQ ID NO: 48, and a pharmaceutical composition containing the antibody used for the treatment of primary amyloidosis. Objects 4-7 represent a method for producing a chimeric antibody and vector constructs 11-1F4VHpG1D200, 11-1F4VK.pKN100 and pG1KD200-11-1F4 used in the preparation. 8, the object is the use of an antibody having a label attached thereto to detect the presence of amyloid deposits. 9-11 objects are chimeric murine and human antibodies produced by the methods of the invention. Objects 12 and 13 are polypeptides that are antibody regions VKof SEQ ID NO: 47 and VHof SEQ ID NO: 48. Objects 14 and 15 are polynucleotides of SEQ ID NO: 42 and SEQ ID NO: 45 encoding these polypeptides.EFFECT: technical result consists in treating primary amyloidosis and detecting the presence of amyloid deposits using the antibodies according to the invention.22 cl, 6 tbl, 6 ex, 8 dwg
Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks.
OBJECTIVES: Acinetobacter baumannii is classified by the centre for Disease Control and Prevention (CDC) as an "urgent threat" due to its ability to acquire and develop resistance to multiple classes of antibiotics. As a result, it is one of the most concerning pathogens in healthcare settings, with increasing incidence of infections due to carbapenem-resistant Acinetobacter baumannii (CRAB) associated with high morbidity and mortality rates. Therefore, there are ongoing efforts to find novel treatment options, one of which is cefiderocol. We aim to review available evidence on cefiderocol use for severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumannii.
METHODS: A comprehensive review was conducted from 2017 to 2023, covering articles from databases such as Pubmed, Scopus, and Embase, along with conference proceedings from ECCMID 2023. The primary focus was on severe nosocomial pneumonia due A. baumannii and cefiderocol.
DISCUSSION: Cefiderocol, targeting periplasmic space Penicillin-Binding Proteins (PBPs) via siderophore transport pathways, exhibits promise against multi-drug resistant Gram-negative bacilli. Its effectiveness in treating CRAB pneumonia remains debated. The CREDIBLE trial reported higher mortality with cefiderocol compared to the best available treatment, while other cohort studies showed contrasting outcomes. Patient variations and pharmacokinetic factors may underlie these discrepancies. The recommended cefiderocol dosage regimen may fall short of desired pharmacokinetic targets, especially in critically ill patients and lung infections. Pulmonary factors hindering cefiderocol's entry into bacteria through iron transporters are overlooked in clinical breakpoints. Optimized dosing or combination regimens may enhance infection site exposure and outcomes.
CONCLUSIONS: Further research is needed to determine the optimal cefiderocol dosage and administration (mono vs. dual therapy, continuous vs. intermittent infusion), in severe Acinetobacter baumannii nosocomial pneumonia.
Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
PURPOSE:To obtain a substance FR-900220 which is a novel pharmacologically active substance, by cultivating a strain belonging to the genus Amauroascus. CONSTITUTION:A strain No. 6237 belonging to the genus Amauroascus is cultivated to give a novel substance FR-900220 having the hypotensive, protective action on infection and suppressing action on gastric juice secretion. The resultant substance has a molecular formula expressed by the formula, 508.2825 molecular weight and 156-158 deg.C melting point. The cultivation is carried out in a culture medium containing glucose, sucrose or maltose, etc. as a carbon source, meat extract, peptone or gluten meal, etc. as a nitrogen source and disodium hydrogenphosphate, magnesium chloride or calcium carbonate, etc. as an inorganic culture method.
Patients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise. In such cases, white-blood-cell and differential counts should be obtained to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.

### Laboratory Tests

Because methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures.

Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of methimazole should be employed.
After extensive clinical use of chlorzoxazone-containing products, it is apparent that the product is well tolerated and seldom produces undesirable side effects. Occasional patients may develop gastrointestinal disturbances. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or overstimulation may be noted by an occasional patient. Rarely, allergic-type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.

To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals, Inc., at 1-866-562-4597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
There will be a rapid surge in research about molecular residual disease (MRD) for solid cancer in the near future. However, MRD differed significantly between tumor types and between contexts; there continues to be a considerable lack of awareness and knowledge about using MRD in lung cancer. Hence, this study aims to investigate the value of MRD in NSCLC patients who underwent complete resection. Preoperative blood sample (20ml), tumor tissue and dynamic postoperative blood samples (20ml) are collected continuously for MRD detection. The follow-up was performed once every 3 to 6 months. The primary objective of this study is to assess the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.
PURPOSE:To decolor human serum albumin useful, e.g. for therapy of e.g. hypoalbuminemia or fetal erythroblastosis caused by surgery, shock, burn or edema by heat-treating human serum albumin manifested by a gene manipulation under a condition in which free polysaccharides are removed. CONSTITUTION:A recombinant plasmid integrated with a gene coding human serum albumin is transferred to Pichia pastoris GTS 115 (his 4) to transform it and the resultant transformant is inoculated in a culture medium and subjected to shaking culture at 30 deg.C for 24hr. The culture solution is subsequently compressed to separate the culture supernatant and the resultant culture supernatant is treated with an ultrafiltration membrane having 300000 differential molecular weight. Further, it is treated with another ultrafiltration membrane having 30000 differential molecular weight and the resultant fraction is passed through a cation-exchange resin column and heat-treated at 60 deg.C for 1hr under a condition in which free polysaccharides are removed, thus decoloring and purifying the objective human serum albumin useful, e.g. for therapy of, e.g. hypoalbuminemia or fetal erythroblastosis.
PURPOSE:A composition, containing NaCl, a surfactant and a water-soluble casein, and having improved detergency in the oral cavity and feeling of use without deteriorating the foaming property of the surfactant even in a large amount of the NaCl. CONSTITUTION:A composition for the oral cavity, containing 4-15wt% NaCl, 0.5-5wt% surfactant and 0.5-5wt% water-soluble casein, and usable as a toothpaste, tooth powder, tooth wash and mouthwash, etc. The water-soluble casein preferably has 1g/100ml water (20 deg.C) solubility in water at 7pH, and is obtained by precipitating and separating casein from a skimmilk in an aqueous solution having a pH if necessary adjusted to about the isoelectric point (4.4-4.7pH), and reacting the precipitated casein with an alkali. An anionic surfactant, e.g. sodium lauryl sulfate, ampholytic surfactant, e.g. the imidazoline type, may be used as the surfactant.
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. Most vision loss in this disease results from sequelae of choroidal neovascular membrane (CNVM) formation. CNVM is usually composed of well-formed neovascularization and occult (less well-formed) neovascularization. While clinical trials have shown that some patients, mostly those with well-formed CNVM, may benefit from laser photocoagulation or photodynamic therapy, at present there is no treatment for patients who have a large component of occult neovascularization.

Retinal histopathology of patients with choroidal neovascularization demonstrates the presence of inflammatory and reparative responses. We hypothesize that sustained intraocular corticosteroids may be able to down-regulate many of the cellular factors involved in both inflammation and repair, resulting in stabilization of CNVM formation and vision. We will test this hypothesis using a randomized, prospective study. Persons having an eligible eye with occult choroidal neovascularization will be randomly assigned to receive either a 0.5 microgram/day or a 2 microgram/day sustained-release fluocinolone intravitreal implant. The study is designed to provide limited safety and potential efficacy data regarding these sustained intravitreal devices. The primary outcome of the study will be implant safety as determined by potential, implant related, adverse advents. These events can be related to the surgical insertion of the intravitreal implants, such as endophthalmitis, hypotony, retinal detachment and hemorrhage, those related to complications of the anesthesia, such as retrobulbar hemorrhage or complications of general anesthesia, if used, and those related to intraocular fluocinolone such as development of glaucoma and cataract formation. The primary efficacy outcome will be proportion of patients, at two years, who have not lost two lines or more of visual acuity from baseline (best corrected visual acuity has improved, remained stable, or deteriorated by no more than 9 letters). Secondary efficacy outcome measures will include the size of predominate occult CNVM, as determined by fluorescein angiography, and visual function, as measured by the NEI VFQ. This study will allow investigators to determine some of the potential risks for patients receiving intravitreal fluocinolone and may provide insight into the potential role of the intravitreal placement of steroids in the treatment of predominate occult CNVM associated with AMD.
Astrocytes play an important role in neuroinflammation by producing proinflammatory molecules. In response to various stressful stimuli, astrocytes can become senescent or reactive, both are present in age-associated cognitive impairment and other neurodegenerative diseases, and contribute to neuroinflammation. However, there are no studies that compare the cytokines secreted by these types of astrocytes in the brain during aging. Hence, we aimed to broaden the picture of the secretory profiles and to differentiate the variability between them. Therefore, a systematic review was conducted following the guidelines of the "Reporting Items for Systematic Review and Meta-Analyses". Only three studies that met the inclusion terms evaluated age-related cytokine secretion, however, no evaluation of senescence or gliosis was performed. Consequently, to increase the spectrum of the review, studies where those phenotypes were induced and cytokines determined were included. Although some cytokines were common for gliosis and senescence, some interesting differences were also found. The dissimilarities in cytokines secretion between these phenotypes could be studied in the future as potential markers.
PURPOSE:An agent, containing 1-methyl-4,5-dihydroorotyl-histidyl-prolinamide as an active ingredient and useful for treating central nervous disorder, e.g. disturbance of consciousness, senile dementia, etc., and hardly causing side effect. CONSTITUTION:A remedy containing 1-methyl-4,5-dihydroorotyl-histidyl- prolinamide expressed by the formula or an acid addition salt thereof as an active ingredient. The compound expressed by the formula has improved arousal promoting action and pentobarbital anesthetic antagonistic action, is capable of remarkably activating acetylcholine neuron of hypothalamus, brain stem reticular formation, brain cortex and hippocampus and suitable as a remedy for disturbance of consciousness and senile dementia and further exhibiting increasing action on conductivity and excitability of spinal movement neuron membrane and usable for treating spinocerebellar deformity. The agent has relatively less side effect (TSH releasing action, etc.) and higher safety than TRH and various derivatives thereof.